You are here
The burden of anaemia in patients with inflammatory bowel diseases
Digestive and Liver Disease, In Press, Corrected Proof, Available online 22 November 2015, Available online 22 November 2015
Anaemia (AN) is frequently associated with inflammatory bowel diseases (IBD) and can negatively influence the quality of life of patients.
To evaluate the prevalence and causes of AN in IBD.
We prospectively performed a one-year multicentre observational study including all IBD cases attending six Units. We also investigated patients’ main serological parameters.
The study population included 965 IBD patients (582 CD; 383 UC), of whom 142 were in-patients and 823 out-patients. AN was diagnosed in 134 out of 965 IBD patients (14%). No significant difference in AN prevalence was observed between CD and UC. The prevalence of AN was higher in the hospitalized IBD (26% in- vs. 11.7% out-patients; p < 0.01; OR 2.2) and in active disease (CD: 34% active vs. 16% inactive; p < 0.01; OR 2.1 – UC: 26% active vs. 19% inactive; p = 0.03; OR 1.3). Iron deficiency was present in 72 patients (53.7%), AN of chronic diseases in 12 (8.2%), mixed type AN in 11 (8.2%), thalassemia in 9 (6.7%), and macrocytic AN in 8 (5.9%).
In Southern Italy, AN is common in IBD and is more frequent in active disease and hospitalized patients. Iron deficiency still remains the major cause of AN in IBD.
Keywords: Anaemia, Crohn's disease, IBD, Ulcerative colitis.
Inflammatory bowel diseases (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC), are a group of chronic inflammatory conditions affecting the gastrointestinal tract. One of the most frequent extra-intestinal manifestations (EIMs) of IBD is anaemia (AN) which affects patients’ quality of life  and , potentially limiting their ability to work .
The reported prevalence of AN in patients with IBD varies from 6% to 74%. A recent systematic review of manuscripts published between 2007 and 2012, reported a prevalence of AN of 27% in patients with CD and of 21% in patients with UC . The aforementioned variability in the AN prevalence depends on different factors. First of all, a review of several studies showed that the definition of AN is not homogeneous. In fact, the widely accepted World Health Organization criteria for the diagnosis of AN [haemoglobin (Hb) below 13 g/dL in men or 12 g/dL in non-pregnant women]  has been questioned because it fails to consider racial differences, environmental conditions and eating habits  and . Therefore, its use cannot appropriately reflect the actual prevalence of AN in different IBD populations.
Furthermore, the prevalence of AN often depends on the peculiarities of the groups of patients studied (e.g. hospitalized patients vs. outpatients). In this sense, many studies showed a higher prevalence of AN in hospitalized UC and CD patients than among outpatient populations , , , and . AN prevalence in hospitalized IBD patients ranges from 44%, as reported by Hoffbrand et al. , up to 74%, as found by Werlin and Grand . However, the latter numbers were reported in older studies from the 60s and 70s and, obviously, the prevalence has decreased through the years mainly due to better treatment. Finally, the presence of AN correlates directly with disease activity, which means that its prevalence may change throughout the natural history of the disease .
A crucial role in iron homeostasis is played by hepcidin, a protein produced by hepatocytes, macrophages and adipocytes. Hepcidin inhibits the transport of iron into the plasma from the macrophages or the enterocytes involved in the absorption of dietary iron. Hepcidin fulfils its function by binding and inhibiting ferroportin (located on the basal lamina of the enterocyte) that is so internalized and degraded. In this way the iron, even if it is properly introduced and absorbed, is stored in the bowel deposits and therefore not present in the circulation. Increased hepcidin activity is partially responsible for reduced iron availability seen in anaemia of chronic inflammation. For example, in IBD some pro-inflammatory cytokines (such as IL-6) increases hepcidin, thus determining the sequestration of iron in macrophages and the inability to transport this element in the plasma .
The aim of our study was to evaluate the prevalence and causes of AN in patients with IBD living in Campania, a region of Southern Italy.
2. Patients and methods
From April 2014 to April 2015, we performed a one-year multicentre, prospective, observational study in Campania (Southern Italy), including all consecutive patients with CD and UC, attending six IBD Units. Patients’ characteristics were classified in accordance with the European Crohn's and Colitis Organisation (ECCO) guidelines  and . Patients within the inclusion criteria were enrolled in the study; their demographics, disease-related characteristics, and current medications were recorded and blood samples were collected for haematological assessment. The following data were registered: gender, age, phenotype of disease according to the Montreal classification , incident/prevalent disease and duration of the disease.
Moreover, we investigated the disease activity, using Crohn's Diseases Activity Index (CDAI) and Clinical Activity Index (CAI). In accordance with literature  and , active disease was defined as CDAI ≥ 150 for CD patients and CAI ≥ 5 for UC patients.
According to the World Health Organization, AN was defined in presence of haemoglobin values Hb < 13 g/dl for males and Hb < 12 g/dl for females; severe AN was defined in case of Hb < 10 g/dl . To explore the causes of AN, all anaemic patients underwent a second-line haematological assessment, which included an evaluation of ferritin, transferrin, vitamin B12, folic acid and homocysteine levels, and a screening for celiac disease (total IgA and anti-transglutaminase antibodies). Furthermore, in all IBD cases, CRP and ESR were evaluated. According to literature , iron deficiency AN (IDA) was diagnosed in case of ferritin < 30 ng/ml and transferrin saturation (TSAT) < 16%. AN of chronic disease (ACD) was diagnosed when elevated CRP/ESR values coexisted with TSAT < 16% and ferritin > 100 ng/ml; mixed type AN was considered in case of TSAT < 16% and 30 ng/ml < ferritin < 100 ng/ml. Patients not classifiable according to these definitions were categorized as having “other anaemia”.
All patients gave their written consent to participate in the study.
2.1. Statistical analysis
Statistical analysis was performed using Chi-square and Mann Whitney U test, ANOVA and odd ratio (OR), when appropriate. A p-value lower than 0.05 was considered significant.
Statistical analysis was carried out using SPSS software package for Windows.
The study population included 965 IBD patients (582 CD; 383 UC; 357 incident cases, 608 prevalent cases) of whom 142 were in- and 823 were out-patients. Baseline characteristics of patients are summarized in Table 1.
|Ulcerative colitis||Crohn's disease|
|Mean age||39 (16–67)||33 (15–64)|
|CAI (mean ± SD)||8 (±2)||–|
|CDAI (mean ± SD)||–||280 (±70)|
AN was diagnosed in 134 out of 965 IBD patients (14%). The principal features of anaemic subjects are shown in Table 2. No significant difference was observed between CD and UC groups (81 CD vs. 53 UC; 13.9% vs. 13.8%; p = n.s.). We found severe anaemia in 12% of patients, with no difference between patients with CD and those with UC (Table 3).
|Ulcerative colitis||Crohn's disease|
|Mean age||38 (18–62)||35 (17-60)|
|CAI (mean ± SD)||9 (±2)||–|
|CDAI (mean ± SD)||–||300 (±60)|
|Hemoglobin (mean ± SD)||10.8 (±1.1)||10.9 (±1)|
|Ferritin (mean ± SD)||70 ± 132.4||44 ± 80.4|
|CRP (mean ± SD)||6.5 (±12.1)||7.2 (±13)|
|CD (81)||41 (50.6)||7 (8.6)||7 (8.6)||6 (7.4)||7 (8.6)||13 (16)|
|UC (53)||31 (58.4)||5 (9.4)||4 (7.5)||3 (5.6)||1 (1.8)||9 (16.9)|
|IBD||72 (53.7)||12 (8.2)||11 (8.2)||9 (6.7)||8 (5.9)||22 (16.4)|
IDA: ferritin < 30 ng/ml and TSAT < 16%; ACD: elevated CRP/ESR values coexisted with TSAT < 16% and ferritin > 100 ng/ml; mixed AN: TSAT < 16% and 30 ng/ml < ferritin < 100 ng/ml. Patients not falling into any of these categories are classified as having “other anaemia”.
Age, gender and concurrent therapy appeared to have no influence on the prevalence of anaemia.
When considering the incident/prevalent cases, AN was evident in 54 incident cases vs. 80 prevalent cases of IBD (15% vs. 13%; p = 0.3); no difference was seen between CD and UC groups. The prevalence of AN was higher in the hospitalized IBD group (26% in- vs. 11.7% out-patients; p < 0.01; OR 2.2) and in patients with active disease (CD: 34% active vs. 16% in remission; p < 0.01; OR 2.1 – UC: 26% active vs. 19% in remission; p = 0.03; OR 1.3) (Table 4). To test whether the location/extension of the disease correlated with AN, we stratified the data set so that our results showed AN to be more frequent in patients with ileo-colic CD and in those with extensive UC (p < 0.01). We found anaemia in 82.7% of CD patients with ileo-colic disease vs. 17.3% with colic disease and in 60.9% of UC patients with extensive colitis vs. 39.1% of patients with left colitis/proctitis. For what concerns the causes of AN, IDA was found in 72 patients (53.7%), ACD in 12 (8.2%), mixed type AN in 11 (8.2%), thalassemia in 9 (6.7%), and macrocytic AN in 8 patients (5.9%) (Fig. 1). We found azathioprine-related macrocytic anaemia in 3 patients (2.2%). In 18 patients (13.4%), the causes remained unclassifiable. Additionally, vitamin B12 deficiency and folic acid deficiency were observed in 7.4% and 6.1% of CD patients and in no case of UC. No case of celiac disease was detected in our IBD population.
|UC (n = 383)||CD (n = 582)||p-Value|
|Entity of disease (%)||53 (13.8)||81 (13.9)||n.s.|
|Mean age||38 (18–62)||35 (17–60)||n.s.|
|n (%) women||32 (8.1)||47 (8)||n.s.|
|n (%) men||21 (5.5)||34 (5.8)||n.s.|
|Ferritin (mean ± SD)||44 ± 80.4||70 ± 132.4||p < 0.01|
|CRP (mean ± SD)||6.5 (±12.1)||7.2 (±13)||n.s.|
|Hosp/outpatients (%)||14 (3.6)/9 (2.3)||p < 0.01|
|Hosp/outpatients (%)||20 (3.4)/6 (1)||p < 0.01|
|Active disease (%)||198 (34)||p < 0.01|
|Active disease (%)||99 (26)||p = 0.03|
|Location n (%)|
|L1-L2-L3||14 (18)-20 (24)-47 (58)||p < 0.01|
|Extension n (%)|
|E1-E2-E3||4 (7)-17 (32)-32 (61)||p < 0.01|
ACD was associated with higher CRP values than IDA, although no differences were observed in disease activity scores between patients with ACD and IDA. In CD patients, mean CDAI was 190 in IDA vs. 230 in ACD (p = n.s.), while in UC patients mean CAI was 8 in patients with IDA vs. 9 in patients with ACD (p = n.s.).
While patients with CD had Hb, TSAT, and CRP values comparable to those of patients with ulcerative colitis, their serum ferritin values were higher (70 ± 132.4 vs. 44 ± 80.4; p < 0.01).
Since ferritin is recognized as an acute-phase protein, we further assessed the correlation of ferritin with CRP as well as with disease activity index. We found that 17% of patients with increased ferritin levels presented elevated disease activity. However, there was no correlation between the grade of inflammation, as measured by CRP or CDAI/CAI, and ferritin (p = n.s.).
Data concerning the prevalence of AN in IBD ranges from 6% to 74%  and . In our work, we found AN in 14% of patients, a quite lower value than the one reported in other studies  and . This discrepancy was probably influenced by the fact that, while we evaluated only patients under active treatment, the latter two studies included subjects who had yet to start therapy. Moreover, our results showed no significant difference between CD and UC groups. Besides chronic intestinal blood loss through ulcerated mucosal surface, which occurs in both disease entities, patients with CD in the upper gastrointestinal regions (e.g. jejunum, ileum) have an additional risk of iron malabsorption leading to IDA. However, in our study population, this difference was not clearly evident. Moreover, we did not find discrepancies between men and women, indicating that blood loss during menstruations in young females does not significantly affect overall iron status.
In our work, most cases of AN were classified as either mild or moderate (HB ≥10 g/dl), according to a recent European study  in which 91.2% of IBD patients presented HB levels ≥ 10 g/dl. The German AnaemIBD Study included only IBD outpatients, and, as a consequence, probably disregarded potential cases with a more severe AN, needing hospitalization. On the contrary, we included both in- and out-patients, and, therefore, the low rate of severe AN found was probably the result of a major control of the disease. However, our hospitalized patients were more frequently anaemic than out-patients, showing that AN could be a complication of IBD that requires careful monitoring and prompt treatment.
As shown by our data, the most frequent cause of AN, in both CD and UC patients, was iron deficiency, which was probably related to the longer course of the disease, and/or chronic overt/occult blood loss.
Iron deficiency may be related to “absolute iron deficiency” due to low dietary intake and blood loss from ulcerated intestinal mucosa (especially in UC) along with reduced iron absorption (especially in CD localized in the upper GI tract), or it may be related to “functional iron deficiency”. In case of “functional deficiency”, even if iron is abundant in the body, it is not available for erythropoiesis because some events cause its retention in the cells: inhibition of ferroportin transcription and activity, and reduced erythrocytes half-life due to oxidative stress and lipid peroxidation . In our study, 53.7% of patients showed IDA and there was no difference between CD and UC. Among patients with IDA, 48 of them (66%) were treated with iron therapy: 3 patients (6.2%) received transfusion, 30 subjects (62.5%) were treated with oral iron and 15 of them (31%) received parenteral iron. We also found that 8.2% of subjects showed ACD, caused by decreased erythropoiesis due to pro-inflammatory cytokines (INFγ, IFNα, TNFα and IL-1).
Another cause of AN was macrocytic AN, that affected 5.9% of patients, and was probably induced by concomitant treatment with thiopurines (3 patients with CD treated with azathioprine for 2 years, 3 years and 5 years, respectively) or by poor absorption of folic acid and vitamin B12 after surgery, in case of CD (5 patients, 3.7%). Among other causes of AN (16.4%), we would like to report autoimmune hemolytic anaemia (AIHA), which was found in two patients with UC during therapy with azathioprine (one young man) and infliximab (one young woman). This condition was induced by the development of antibodies with cross-reactivity with erythrocytes .
For what concerns the correlation of AN with the location/extension of the disease, anaemia appeared to be more frequent in patients with ileo-colic CD and in those with extensive UC (p < 0.01). In fact, 82.7% of anaemic CD patients showed an ileo-colic location vs. 17.3% of subjects with a colic disease. On the other hands, 60.9% of anaemic UC patients showed an extensive colitis vs. 39.1% of patients with distal colitis or proctitis. In CD, these findings could support the argument that small bowel inflammation has a major role in determining iron malabsorption and, consequently, IDA. In UC, the correlation between low Hb levels and the extension of the disease, highlighted the importance of a greater inflamed surface in which ulcerations and erosions represent the principal bleeding source.
Moreover, some studies have found a correlation between high CDAI and AN; this result is not surprising, considering that the hematocrit value is a parameter for the calculation of CDAI. In our subjects, we found that ACD was associated with higher CRP values than IDA, although no difference was observed about disease activity scores between patients with ACD and IDA. Perhaps, no significant correlation was evident between Hb values and activity of disease, because our patients were evaluated during a mild/moderate phase of the disease. Additionally, we measured patients’ iron status at a single time-point, without considering a temporal evaluation of AN over time. Therefore, it would be interesting to assess any changes in haemoglobin level after the treatment of the underlying disease in a future prospective study.
Unexpectedly, no case of celiac disease was observed in our IBD population. This outcome conflicts with the expected data in a geographical area which is characterized by a high prevalence of celiac disease (prevalence: 1–2/100 inhabitants) .
In conclusion, our results confirmed that anaemia has a significant impact on IBD and represents one of the most frequent conditions associated with such diseases. Prompt diagnosis and careful treatment of anaemia in IBD should become a major concern for gastroenterologists experienced in IBD work-up.
Conflict of interest
Many thanks to Dr. Manuela Pignata for the revision of English language and her precious support.
-  L.T. Pizzi, C.M. Weston, N.I. Goldfarb, et al. Impact of chronic conditions on quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2006;12:47-55
-  C.W. Wells, S. Lewis, J.R. Barton, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflammatory Bowel Diseases. 2006;12:123-130 Crossref
-  C. Cucino, A. Sonnenberg. Cause of death in patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2001;7:250-255 Crossref
-  N. Filmann, J. Rey, S. Schneeweiss, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: a systematic review and individual patient data meta-analysis. Inflammatory Bowel Diseases. 2014;:1-10
-  World Health Organization. Iron deficiency anemia assessment, prevention and control a guide for programme managers. Report. (WHO/NHP/01.3, 2011)
-  E. Beutler, J. Waalen. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?. Blood. 2006;107:1747-1750 Crossref
-  K.V. Patel, T.B. Harris, M. Faulhaber, et al. Racial variation in the relationship of anemia with mortality and mobility disability among older adults. Blood. 2007;109:4663-4670 Crossref
-  M. Rejler, J. Tholstrup, B. Andersson-Gäre, et al. Low prevalence of anemia in inflammatory bowel disease: a population-based study in Sweden. Scandinavian Journal of Gastroenterology. 2012;47:937-942 Crossref
-  S. Kulnigg, C. Gasche. Systematic review: managing anemia in Crohn’ s disease. Alimentary Pharmacology and Therapeutics. 2006;24:1507-1523 Crossref
-  J.P. Gisbert, F. Gomollón. Anemia and inflammatory bowel diseases. World Journal of Gastroenterology. 2009;15:4659-4665
-  A. Wilson, E. Reyes, J. Ofman. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. American Journal of Medicine. 2004;116(Suppl. 7A):44S-49S
-  A.V. Hoffbrand, J.S. Stewart, C.C. Booth, et al. Folate deficiency in Crohn's disease: incidence, pathogenesis and treatment. British Medical Journal. 1968;2:71-75 Crossref
-  S.L. Werlin, R.J. Grand. Severe colitis in children and adolescents: diagnosis. Course and treatment. Gastroenterology. 1977;73(Pt 1):828-832
-  A. Vijverman, P. Piront, J. Belaiche, et al. Evolution of the prevalence and characteristics of anemia in inflammatory bowel diseases between 1993 and 2003. Acta Gastro-Enterologica Belgica. 2006;69:1-4
-  F. Gomollon, J.P. Gisbert. Anemia and inflammatory bowel diseases. World Journal of Gastroenterology. 2009;15:4659-4665 Crossref
-  W. Reinisch, M. Staun, S. Bhandari, et al. State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. Journal of Crohn's and Colitis. 2013;7:429-440 Crossref
-  G. Van Assche, A. Dignass, J. Panes, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Journal of Crohn's and Colitis. 2010;4:7-27 Crossref
-  A. Dignass, R. Eliakim, F. Magro, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. Journal of Crohn's and Colitis. 2012;6:965-990 Crossref
-  J. Satsangi, M.S. Silverberg, S. Vermeire, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus and implications. Gut. 2006;55:749-753
-  R.S. Walmsley, R.C. Ayres, R.E. Pounder, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32 Crossref
-  A. Dignass, C. Gasche, D. Bettenworth, et al. European consensus on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Journal of Crohn's and Colitis. 2015;:1-12
-  G. Bergamaschi, A. Di Sabatino, R. Albertini, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment. Haematologica. 2010;95:199-205 Crossref
-  M.L. Høivik, W. Reinisch, M. Cvancarova, et al. Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Alimentary Pharmacology and Therapeutics. 2014;39:69-76
-  I. Blumenstein, A. Dignass, S. Vollmer, et al. Current practice in the diagnosis and management of IBD-associated anemia and iron deficiency in Germany: the German AnaemIBD Study. Journal of Crohn's and Colitis. 2014;8:1308-1314 Crossref
-  M.D. Knutson, M. Oukka, L.M. Koss, et al. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:1324-1328 Crossref
-  A. Rispo, D. Musto, M.L. Tramontano, et al. Surgery-induced remission of extraintestinal manifestations of inflammatory bowel diseases. Journal of Crohn's and Colitis. 2013;7:e504-e505 Crossref
-  F. Zingone, J. West, R. Auricchio, et al. Incidence and distribution of coeliac disease in Campania (Italy): 2011–2013. United European Gastroenterol Journal. 2015;3:182-189 Crossref
a Department of Clinical Medicine and Surgery, University “Federico II” of Naples, Naples, Italy
b Department of Clinical and Experimental Medicine “Magrassi-Lanzara”, Gastroenterology Unit, Second University of Naples, Naples, Italy
c Gastroenterology Unit, Second University of Naples, Naples, Italy
d Surgery, Second University of Naples, Naples, Italy
e Hospital of Marcianise, Caserta, Italy
f Hospital of Sapri, Salerno, Italy
⁎ Corresponding author at: Gastroenterologia, Università degli Studi di Napoli “Federico II”, Scuola di Medicina e Chirurgia, Via S. Pansini 5, 80131 Naples, Italy. Tel.: +39 0817463849; fax: +39 0817463849.
© 2015 Editrice Gastroenterologica Italiana S.r.l., Published by Elsevier B.V.